FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

FDA Approval of Prostate Cancer Imaging Agent a Milestone for Inventor and Johns Hopkins

The U.S. Food and Drug Administration recently approved the first commercially available positron emission tomography (PET) imaging agent targeting the prostate-specific membrane antigen (PSMA). This represents the culmination of 25 years of work for Martin Pomper, M.D., Ph.D., a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Read more about this innovation here.

SEE ALL NEWS
Recent Posts
Six Mammogram Myths Active Care Model Predicts Disease Course for Prostate Cancers 20-year study shows that lung cancer screening boosts survival rates The Surprising Health Bonus of Caregiving Podcast: Breast Imaging New Microscopy Method Detects Treatment-resistant Cancer Cells Early Reduce Your Breast Cancer Risk Novel Blood Test May Detect Cancer Stress Busters: 4 Integrative Treatments